Dual inhibition of epidermal growth factor and insulin-like 1 growth factor receptors reduce intestinal adenoma burden in the Apc(min/+) mouse

BACKGROUND: Identification of early molecular pathway changes may be useful as biomarkers for tumour response/resistance prediction, and here we provide direct in vivo proof of this concept. The type 1 insulin-like growth factor receptor (IGF1R) has been implicated in various aspects of adenoma deve...

Descripción completa

Detalles Bibliográficos
Autores principales: Shaw, P H S, Maughan, T S, Clarke, A R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2011
Materias:
Translational Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3188935/
https://www.ncbi.nlm.nih.gov/pubmed/21811251
http://dx.doi.org/10.1038/bjc.2011.291

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3188935/
https://www.ncbi.nlm.nih.gov/pubmed/21811251
http://dx.doi.org/10.1038/bjc.2011.291

Ejemplares similares